JP2019501973A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019501973A5 JP2019501973A5 JP2018555314A JP2018555314A JP2019501973A5 JP 2019501973 A5 JP2019501973 A5 JP 2019501973A5 JP 2018555314 A JP2018555314 A JP 2018555314A JP 2018555314 A JP2018555314 A JP 2018555314A JP 2019501973 A5 JP2019501973 A5 JP 2019501973A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- antibody
- cancer
- cell
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 34
- 210000001744 T-lymphocyte Anatomy 0.000 claims 13
- 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 claims 11
- 231100000617 superantigen Toxicity 0.000 claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 201000011510 cancer Diseases 0.000 claims 10
- 239000000427 antigen Substances 0.000 claims 9
- 108091007433 antigens Proteins 0.000 claims 9
- 102000036639 antigens Human genes 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 8
- 125000000539 amino acid group Chemical group 0.000 claims 6
- 230000000091 immunopotentiator Effects 0.000 claims 5
- 230000004913 activation Effects 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 230000011664 signaling Effects 0.000 claims 4
- 230000008685 targeting Effects 0.000 claims 4
- 101710160107 Outer membrane protein A Proteins 0.000 claims 3
- 239000003623 enhancer Substances 0.000 claims 3
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 2
- 108091008874 T cell receptors Proteins 0.000 claims 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 2
- 229960003852 atezolizumab Drugs 0.000 claims 2
- 230000005754 cellular signaling Effects 0.000 claims 2
- 229950009791 durvalumab Drugs 0.000 claims 2
- 231100000655 enterotoxin Toxicity 0.000 claims 2
- 230000001900 immune effect Effects 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 229960003301 nivolumab Drugs 0.000 claims 2
- 230000037361 pathway Effects 0.000 claims 2
- 229960002621 pembrolizumab Drugs 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000000638 stimulation Effects 0.000 claims 2
- 230000001629 suppression Effects 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662276955P | 2016-01-10 | 2016-01-10 | |
| US62/276,955 | 2016-01-10 | ||
| PCT/IB2017/000511 WO2017122098A2 (en) | 2016-01-10 | 2017-01-10 | Methods and compositions for enhancing the potency of superantigen mediated cancer immunotherapy. |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019501973A JP2019501973A (ja) | 2019-01-24 |
| JP2019501973A5 true JP2019501973A5 (enExample) | 2020-02-20 |
| JP7161938B2 JP7161938B2 (ja) | 2022-10-27 |
Family
ID=58737690
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018555314A Active JP7161938B2 (ja) | 2016-01-10 | 2017-01-10 | スーパー抗原媒介性癌免疫療法の能力を増強するための方法および組成物 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US10314910B2 (enExample) |
| EP (1) | EP3411409B1 (enExample) |
| JP (1) | JP7161938B2 (enExample) |
| KR (2) | KR20250071286A (enExample) |
| CN (2) | CN109195988B (enExample) |
| AU (1) | AU2017206656B2 (enExample) |
| CA (1) | CA3010678A1 (enExample) |
| EA (1) | EA201891601A1 (enExample) |
| ES (1) | ES3052659T3 (enExample) |
| IL (1) | IL260423B2 (enExample) |
| MX (1) | MX2018008383A (enExample) |
| WO (1) | WO2017122098A2 (enExample) |
| ZA (1) | ZA201804565B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3411409B1 (en) | 2016-01-10 | 2025-10-08 | Neotx Therapeutics Ltd. | Anti pd-1/anti-pd-l1 antibodies for enhancing the potency of superantigen mediated cancer immunotherapy |
| EP3793585A4 (en) * | 2018-05-16 | 2022-02-23 | Duke University | NEADJUVANT CANCER TREATMENT COMPRISING THE COMBINATION OF AN IMMUNOTOXIN AND A CHECKPOINT INHIBITOR |
| CN108840923B (zh) * | 2018-06-22 | 2021-08-03 | 上海交通大学医学院附属仁济医院 | 一种靶向pd-l1的多肽及其应用 |
| EA202193121A1 (ru) * | 2019-05-15 | 2022-02-21 | Неоткс Терапьютикс Лтд. | Лечение рака |
| WO2021087105A1 (en) | 2019-10-30 | 2021-05-06 | Duke University | Immunotherapy with combination therapy comprising an immunotoxin |
| CN115484978A (zh) * | 2020-03-05 | 2022-12-16 | 尼奥克斯医疗有限公司 | 使用免疫细胞治疗癌症的方法和组合物 |
| CN116490521A (zh) * | 2020-07-20 | 2023-07-25 | 尼奥克斯医疗有限公司 | 用于治疗癌症的方法和组合物中的超抗原偶联物 |
| JP7570653B2 (ja) * | 2020-08-19 | 2024-10-22 | ▲蘇▼州易慕峰生物科技有限公司 | ヒト化抗体、キメラ抗原受容体、核酸、ベクター、細胞及び応用 |
| WO2022224041A1 (en) * | 2021-04-22 | 2022-10-27 | Neotx Therapeutics Ltd. | Methods and compositions for treating glioblastoma |
| CA3258344A1 (en) | 2022-06-07 | 2023-12-14 | Actinium Pharmaceuticals, Inc. | CHELETARIANS AND BIFUNCTIONAL CONJUGATES |
| CN116284448B (zh) * | 2023-02-14 | 2024-06-21 | 浙江大学 | 一种超抗原参与的三功能t细胞衔接器及其应用 |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US6893625B1 (en) | 1986-10-27 | 2005-05-17 | Royalty Pharma Finance Trust | Chimeric antibody with specificity to human B cell surface antigen |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| DE68923027D1 (de) | 1988-03-04 | 1995-07-20 | Cancer Res Campaign Tech | Antigene. |
| US5057604A (en) | 1988-08-03 | 1991-10-15 | Washington University | Novel monoclonal antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5284760A (en) | 1989-04-03 | 1994-02-08 | Feinstone Stephen M | Techniques for producing site-directed mutagenesis of cloned DNA |
| US6042837A (en) | 1989-09-20 | 2000-03-28 | Kalland; Terje | Methods of staphylococcal enterotoxin directed cell-mediated cytotoxicity (SDCC) |
| US5728388A (en) | 1989-10-03 | 1998-03-17 | Terman; David S. | Method of cancer treatment |
| US6126945A (en) | 1989-10-03 | 2000-10-03 | Pharmacia Ab | Tumor killing effects of enterotoxins, superantigens, and related compounds |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5149797A (en) | 1990-02-15 | 1992-09-22 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of rna and production of encoded polypeptides |
| US5220007A (en) | 1990-02-15 | 1993-06-15 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of RNA and production of encoded polypeptides |
| US6197299B1 (en) | 1990-07-20 | 2001-03-06 | Pharmacia & Upjohn Ab | Antibody conjugates |
| US5858363A (en) | 1990-07-20 | 1999-01-12 | Pharmacia & Upjohn Ab | Target specific antibody-superantigen conjugates and their preparation |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| SE9102074D0 (sv) | 1991-07-03 | 1991-07-03 | Kabi Pharmacia Ab | Tomour antigen specific antibody |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
| CA2103887C (en) | 1991-12-13 | 2005-08-30 | Gary M. Studnicka | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| EP0620858B1 (en) | 1991-12-24 | 2003-05-02 | The President And Fellows Of Harvard College | Site-directed mutagenesis of dna |
| JPH08500017A (ja) | 1992-08-17 | 1996-01-09 | ジェネンテク，インコーポレイテッド | 二特異的免疫アドヘジン |
| US5389514A (en) | 1992-08-28 | 1995-02-14 | Fox Chase Cancer Center | Method for specifically altering the nucleotide sequence of RNA |
| US5545716A (en) | 1992-09-08 | 1996-08-13 | University Of Florida | Superantigen agonist and antagonist peptides |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US6066718A (en) | 1992-09-25 | 2000-05-23 | Novartis Corporation | Reshaped monoclonal antibodies against an immunoglobulin isotype |
| US5519114A (en) | 1993-10-29 | 1996-05-21 | University Of Florida Research Foundation, Inc. | Retroviral superantigens, superantigen peptides, and methods of use |
| SE9402430L (sv) | 1994-07-11 | 1996-01-12 | Pharmacia Ab | Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6632441B2 (en) | 1995-06-07 | 2003-10-14 | Regents Of The University Of Minnesota | Mutants of streptococcal toxin a and methods of use |
| US5789166A (en) | 1995-12-08 | 1998-08-04 | Stratagene | Circular site-directed mutagenesis |
| JPH09208491A (ja) * | 1996-01-31 | 1997-08-12 | Asahi Optical Co Ltd | 免疫賦活剤 |
| SE9601245D0 (sv) | 1996-03-29 | 1996-03-29 | Pharmacia Ab | Chimeric superantigens and their use |
| WO1997036614A1 (en) * | 1996-03-29 | 1997-10-09 | Terman David S | Polymerized staphylococcal protein a for treatment of diseases |
| TW517061B (en) | 1996-03-29 | 2003-01-11 | Pharmacia & Amp Upjohn Ab | Modified/chimeric superantigens and their use |
| US6774218B2 (en) | 1996-12-06 | 2004-08-10 | Regents Of The University Of Minnesota | Mutants of streptococcal toxin C and methods of use |
| EP0946730B1 (en) | 1996-12-06 | 2006-03-08 | Regents Of The University Of Minnesota | Mutants of streptococcal toxin c and methods of use |
| WO1998024911A2 (en) | 1996-12-06 | 1998-06-11 | Regents Of The University Of Minnesota | Mutants of streptococcal toxin a and methods of use |
| WO1998026747A2 (en) | 1996-12-17 | 1998-06-25 | Terman David S | Superantigen based methods and compositions for treatment of diseases |
| US7087235B2 (en) | 1997-06-25 | 2006-08-08 | The United States Of America As Represented By The Secretary Of The Army | Fusion protein of streptococcal pyrogenic exotoxins |
| US6713284B2 (en) | 1997-06-25 | 2004-03-30 | The United States Of America As Represented By The Secretary Of The Army | Bacterial superantigen vaccines |
| KR20010022075A (ko) | 1997-07-21 | 2001-03-15 | 존 헤덴스트룀 | T세포활성화를유도하는슈퍼항원접합체에의한표적세포의세포용해 |
| US6872518B2 (en) | 1997-09-22 | 2005-03-29 | University Of Rochester | Methods for selecting polynucleotides encoding T cell epitopes |
| WO1999036433A2 (en) | 1998-01-14 | 1999-07-22 | Morphogenesis, Inc. | Materials and methods for treating oncological disease |
| NZ507886A (en) | 1998-05-19 | 2003-05-30 | Avidex Ltd | Multivalent T cell receptor complexes |
| CA2337966A1 (en) | 1998-07-10 | 2000-01-20 | U.S. Medical Research Institute Of Infectious Diseases | Vaccine against staphylococcus intoxication |
| US20020177551A1 (en) | 2000-05-31 | 2002-11-28 | Terman David S. | Compositions and methods for treatment of neoplastic disease |
| US20040214783A1 (en) | 2002-05-08 | 2004-10-28 | Terman David S. | Compositions and methods for treatment of neoplastic disease |
| US20030157113A1 (en) | 1999-12-28 | 2003-08-21 | Terman David S. | Compositions and methods for treatment of neoplastic disease |
| US20010046501A1 (en) | 2000-03-14 | 2001-11-29 | Johnson Howard M. | Superantigen enhancement of specific immune responses |
| CN101712721A (zh) | 2000-06-05 | 2010-05-26 | 阿尔托生物科学有限公司 | T细胞受体融合物及共轭物以及其使用方法 |
| JP4283430B2 (ja) | 2000-09-26 | 2009-06-24 | 株式会社カネカ | エンテロトキシンの吸着材、吸着除去方法および吸着器 |
| JP2004515479A (ja) | 2000-12-04 | 2004-05-27 | オークランド ユニサーヴィスィズ リミテッド | 免疫調節性構築物およびその使用 |
| CN1369550A (zh) | 2001-02-16 | 2002-09-18 | 沈阳协合集团有限公司 | 一种金黄色葡萄球菌的培养物及其制备方法 |
| SE0102327D0 (sv) | 2001-06-28 | 2001-06-28 | Active Biotech Ab | A novel engineered superantigen for human therapy |
| EP2298809A3 (en) | 2001-07-12 | 2012-02-15 | FOOTE, Jefferson | Super humanized antibodies |
| CA2457652C (en) | 2001-08-31 | 2012-08-07 | Avidex Limited | Soluble t cell receptor |
| WO2003060097A2 (en) | 2002-01-10 | 2003-07-24 | National Jewish Medical And Research Center | USE OF SOLUBLE Ϝδ T CELL RECEPTORS FOR REGULATING T CELL FUNCTION |
| ATE481985T1 (de) | 2002-07-03 | 2010-10-15 | Ono Pharmaceutical Co | Immunpotenzierende zusammensetzungen |
| US6926694B2 (en) | 2003-05-09 | 2005-08-09 | Medsolve Technologies, Llc | Apparatus and method for delivery of therapeutic and/or diagnostic agents |
| WO2006004834A2 (en) | 2004-06-30 | 2006-01-12 | Fiberstars Incorporated | Adjustable-aim light pipe fixture |
| SE0402025D0 (sv) * | 2004-08-13 | 2004-08-13 | Active Biotech Ab | Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| CN104945508B (zh) | 2007-06-18 | 2019-02-22 | 默沙东有限责任公司 | 针对人程序性死亡受体pd-1的抗体 |
| AU2013285355A1 (en) * | 2012-07-06 | 2015-01-29 | Genmab B.V. | Dimeric protein with triple mutations |
| CN112587658A (zh) * | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
| AU2013347838A1 (en) * | 2012-11-26 | 2015-06-11 | Caris Life Sciences Switzerland Holdings Gmbh | Biomarker compositions and methods |
| US20170002060A1 (en) * | 2014-01-08 | 2017-01-05 | Moderna Therapeutics, Inc. | Polynucleotides for the in vivo production of antibodies |
| JP6944369B2 (ja) * | 2014-11-20 | 2021-10-06 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Ｔ細胞活性化二重特異性抗原結合分子ｃｄ３ ａｂｄ葉酸受容体１（ｆｏｌｒ１）及びｐｄ−１軸結合アンタゴニストの併用療法 |
| EP3411409B1 (en) * | 2016-01-10 | 2025-10-08 | Neotx Therapeutics Ltd. | Anti pd-1/anti-pd-l1 antibodies for enhancing the potency of superantigen mediated cancer immunotherapy |
-
2017
- 2017-01-10 EP EP17724437.3A patent/EP3411409B1/en active Active
- 2017-01-10 EA EA201891601A patent/EA201891601A1/ru unknown
- 2017-01-10 CN CN201780016492.5A patent/CN109195988B/zh active Active
- 2017-01-10 AU AU2017206656A patent/AU2017206656B2/en active Active
- 2017-01-10 MX MX2018008383A patent/MX2018008383A/es unknown
- 2017-01-10 KR KR1020257014967A patent/KR20250071286A/ko active Pending
- 2017-01-10 KR KR1020187022673A patent/KR20180100412A/ko not_active Ceased
- 2017-01-10 JP JP2018555314A patent/JP7161938B2/ja active Active
- 2017-01-10 CA CA3010678A patent/CA3010678A1/en active Pending
- 2017-01-10 ES ES17724437T patent/ES3052659T3/es active Active
- 2017-01-10 WO PCT/IB2017/000511 patent/WO2017122098A2/en not_active Ceased
- 2017-01-10 US US15/402,888 patent/US10314910B2/en active Active
- 2017-01-10 CN CN202311526574.8A patent/CN117679499A/zh active Pending
-
2018
- 2018-07-04 IL IL260423A patent/IL260423B2/en unknown
- 2018-07-09 ZA ZA2018/04565A patent/ZA201804565B/en unknown
-
2019
- 2019-05-14 US US16/411,276 patent/US11202829B2/en active Active
- 2019-12-11 US US16/710,432 patent/US11607452B2/en active Active
-
2023
- 2023-02-09 US US18/166,938 patent/US20240100156A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019501973A5 (enExample) | ||
| JP2018501197A5 (enExample) | ||
| HRP20211346T1 (hr) | Kombinirani pripravci za liječenje raka | |
| JP2025172086A5 (enExample) | ||
| JP2018508483A5 (enExample) | ||
| Duarte et al. | Gastric cancer: Basic aspects | |
| RU2013141976A (ru) | Новые модуляторы и способы их применения | |
| MX2009010120A (es) | Proteinas de union, incluyendo anticuerpos, derivados de anticuerpo y fragmentos de anticuerpo, que se unen especificamente cd154 y sus usos. | |
| IL265541B2 (en) | Bispecific antibodies and compounds containing them for the treatment of cancer | |
| JP2018538274A5 (enExample) | ||
| JP2017506217A5 (enExample) | ||
| JP2018531914A5 (enExample) | ||
| IL253462B (en) | Cancer treatment with monoclonal antibodies against latency-associated peptide | |
| JP2018515474A5 (enExample) | ||
| JP7370376B2 (ja) | Ｍｉｃａ／ｂシェディングをブロックする抗ｍｉｃａ／ｂ抗体および使用方法 | |
| RU2019102009A (ru) | Специфические антитела к pd-l1 и способы их применения | |
| JP2016539083A5 (enExample) | ||
| WO2014012007A4 (en) | Rspo3 binding agents and uses thereof | |
| CA2786479A1 (en) | Methods for treating pancreatic cancer | |
| US10752688B2 (en) | Anti-human TIM-3 antibodies and methods of use thereof | |
| JP2020522512A5 (enExample) | ||
| Pan et al. | Characterization of a novel bispecific antibody targeting tissue factor-positive tumors with T cell engagement | |
| EA202192587A1 (ru) | Антитела к cd73, антитела к pd-l1 и химиотерапия для лечения опухолей | |
| FI3452515T3 (fi) | HER-2 sitoutuvia vasta-aineita | |
| Mazor et al. | Anti-drug antibodies to LMB-100 are enhanced by mAbs targeting OX40 and CTLA4 but not by mAbs targeting PD1 or PDL-1 |